CR20200291A - Composiciones y métodos para el tratamiento de enfermedades metabólicas - Google Patents

Composiciones y métodos para el tratamiento de enfermedades metabólicas

Info

Publication number
CR20200291A
CR20200291A CR20200291A CR20200291A CR20200291A CR 20200291 A CR20200291 A CR 20200291A CR 20200291 A CR20200291 A CR 20200291A CR 20200291 A CR20200291 A CR 20200291A CR 20200291 A CR20200291 A CR 20200291A
Authority
CR
Costa Rica
Prior art keywords
compositions
treatment
methods
metabolic conditions
conditions
Prior art date
Application number
CR20200291A
Other languages
English (en)
Inventor
Wyk Mariette Luise Van
Peter Pacult
Michael A Volk
James Ervin
Wyk Hendrik Johanness Petrus Van
Brian David Denomme
Original Assignee
Reven Ip Holdco Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reven Ip Holdco Llc filed Critical Reven Ip Holdco Llc
Publication of CR20200291A publication Critical patent/CR20200291A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La presente invención se relaciona con composiciones terapéuticas estables de ácidos y agentes reguladores del pH de grado farmacéutico. También se refiere a métodos de tratamiento para trastornos mitocondriales, enfermedades metabólicas, diabetes y enfermedades cardiovasculares, mediante la administración composiciones de acuerdo con la presente invención.</p>
CR20200291A 2017-12-07 2018-12-07 Composiciones y métodos para el tratamiento de enfermedades metabólicas CR20200291A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762595909P 2017-12-07 2017-12-07
PCT/US2018/064610 WO2019113543A1 (en) 2017-12-07 2018-12-07 Compositions and methods for the treatment of metabolic conditions

Publications (1)

Publication Number Publication Date
CR20200291A true CR20200291A (es) 2020-11-18

Family

ID=66750649

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200291A CR20200291A (es) 2017-12-07 2018-12-07 Composiciones y métodos para el tratamiento de enfermedades metabólicas

Country Status (18)

Country Link
US (3) US20200289553A1 (es)
EP (1) EP3720421A4 (es)
JP (2) JP2021505673A (es)
KR (1) KR102546138B1 (es)
CN (1) CN111565709A (es)
AU (1) AU2018379078A1 (es)
BR (1) BR112020011417A2 (es)
CA (1) CA3084369A1 (es)
CL (1) CL2020001495A1 (es)
CR (1) CR20200291A (es)
EA (1) EA202091396A1 (es)
IL (1) IL275182B2 (es)
JO (1) JOP20200134A1 (es)
MA (1) MA51056A (es)
MX (1) MX2020005879A (es)
PH (1) PH12020550788A1 (es)
SG (1) SG11202005158PA (es)
WO (1) WO2019113543A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3008699T3 (en) 2017-11-17 2025-03-24 Renovion Inc Stable ascorbic acid compositions and methods of using the same
JP2022536708A (ja) * 2019-06-12 2022-08-18 リーベン アイピー ホールディングカンパニー リミテッド ライアビリティ カンパニー がん患者の予後を改善する方法および組成物
US20220096538A1 (en) * 2020-09-30 2022-03-31 Reven Pharmaceuticals Inc. Pharmaceutical compositions and methods for prevention and/or treatment of inflammation
KR102527526B1 (ko) 2020-11-06 2023-05-02 충북대학교 산학협력단 Ｌｓｔｍ 기반 구조물의 동적특성 자동추출방법 및 이를 수행하는 시스템
WO2022174171A1 (en) * 2021-02-15 2022-08-18 Anp Technologies, Inc. Pharmaceutical composition containing taxane nanoaggregates and use thereof
CA3209890A1 (en) * 2021-02-26 2022-09-01 Kumaresh Soppimath Sodium bicarbonate injectable formulation and methods of use thereof
KR102505980B1 (ko) * 2021-11-12 2023-03-06 알고케어 주식회사 사용자의 현재 건강 상태에 최적화된 제형의 조합을 제공하는 디스펜싱 디바이스와 서버 및 그 동작 방법
IL313997A (en) 2022-01-04 2024-08-01 Renovion Inc Aqueous solution including glutathione salt
US11925703B1 (en) 2022-07-29 2024-03-12 Xellia Pharmaceuticals Aps Liquid composition comprising glucose
WO2024130207A1 (en) * 2022-12-15 2024-06-20 Mars, Incorporated Vitamin b supplementation to treat pituitary pars intermedia dysfunction (ppid) in equids
WO2025015323A2 (en) * 2023-07-13 2025-01-16 Ervin James D Therapeutic blood-acid-shifting compositions and methods

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080886A (en) * 1990-01-05 1992-01-14 Sterling Drug Inc. Pharmaceutical compositions for the prevention and treatment of oxidant injuries
WO1993013660A1 (en) * 1992-01-06 1993-07-22 Health Maintenance Programs, Inc. Pharmaceutically active antioxydant containing composition and the method of its use to prevent and treat restenosis following angioplasty
JPH0959150A (ja) * 1995-08-11 1997-03-04 Roussel Morishita Kk 経静脈用輸液製剤
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
JP2003501488A (ja) 1999-06-11 2003-01-14 ネオルックス コーポレイション 骨髄抑制のための高投与量放射性核種錯体
US20040110684A1 (en) 1999-08-02 2004-06-10 Universite Catholique De Louvain Novel pharmaceutical compositions for modulating angiogenesis
EP1282416A2 (en) * 2000-05-19 2003-02-12 Progenics Pharmaceuticals, Inc. Dehydroascorbic acid formulations and uses thereof
US7122210B2 (en) * 2002-01-11 2006-10-17 Baxter International Inc. Bicarbonate-based solutions for dialysis therapies
WO2005044176A2 (en) 2003-11-10 2005-05-19 Lipogen Ltd. Compositions containing phosphatidic acid, methods of use thereof, methods of manufacture thereof, and articles of manufacture containing same
JP2005179200A (ja) * 2003-12-16 2005-07-07 Terumo Corp ビタミンｂ１類配合輸液剤
EP1731146A4 (en) * 2004-03-05 2009-07-01 Morishige Fumie PREVENTION AND MEASURE AGAINST MITOCHONDRIA ILLNESS
DE102004023828A1 (de) * 2004-05-13 2005-12-08 Fresenius Medical Care Deutschland Gmbh Lösung für die Peritonealdialyse
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
JP4615470B2 (ja) 2006-03-29 2011-01-19 卓郎 簑和田 大脳の認知力を用いた疾患治療・予防の方法および医薬
US7282225B1 (en) 2006-09-27 2007-10-16 Occular Technologies, Inc. Composition and methods for improving retinal health
CN101209344B (zh) * 2006-12-28 2012-07-04 赵超英 高渗液组合物在制备促进伤口愈合的药物中的应用
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
ES2759373T3 (es) * 2008-06-12 2020-05-08 Medtronic Xomed Inc Producto para el tratamiento de heridas crónicas con un sistema extracelular de solvatación de sustancias poliméricas
US9101537B2 (en) 2008-07-25 2015-08-11 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
US9089573B2 (en) 2009-07-22 2015-07-28 University Of Massachusetts Methods and compositions to reduce oxidative stress
WO2011013138A1 (en) * 2009-07-29 2011-02-03 Strides Arcolab Limited Stable multi- vitamin formulations
ES2457641T3 (es) 2009-10-15 2014-04-28 Purecircle Sdn Bhd Procedimiento para preparar rebaudiósido D de pureza elevada
EP2324832B2 (de) * 2009-11-09 2016-11-30 Biogena Naturprodukte GmbH & Co KG Nahrungsergänzungsmittel bei Einnahme von hormonellen Kontrazeptiva
KR101910336B1 (ko) * 2010-05-07 2018-10-22 이에이 파마 가부시키가이샤 비타민 배합 말초 정맥 투여용 영양 수액
WO2012009171A2 (en) * 2010-07-15 2012-01-19 The Schepens Eye Research Institute, Inc. Compositions and methods of treatment of corneal endothelium disorders
JP2013532661A (ja) 2010-07-22 2013-08-19 リベン ファーマシューティカルズ インコーポレイテッド 磁気双極子安定化溶液の使用を含む疾患を処置または改善する方法および行動を向上させる方法
KR20130021958A (ko) * 2011-08-24 2013-03-06 울산대학교 산학협력단 인공 수액
WO2014028945A1 (en) * 2012-08-17 2014-02-20 The Regents Of The University Of California Systems, methods and compositions for improved treatment of acidosis
HUE049292T2 (hu) 2013-08-07 2020-09-28 Yeda Res & Dev A P53 mutánsok újraaktíválására képes peptidek
CN106924744A (zh) * 2015-12-30 2017-07-07 钟术光 一种供注射或口服用的药物载体(或制剂)
EP3419613A4 (en) * 2016-02-23 2019-11-06 Mitronite Inc. COMPOSITIONS AND METHOD FOR IMPROVING MITOCHONDRIAL FUNCTION

Also Published As

Publication number Publication date
EA202091396A1 (ru) 2020-09-02
BR112020011417A2 (pt) 2020-11-24
CA3084369A1 (en) 2019-06-13
US20200289553A1 (en) 2020-09-17
EP3720421A1 (en) 2020-10-14
KR102546138B1 (ko) 2023-06-23
IL275182B1 (en) 2023-12-01
IL275182B2 (en) 2024-04-01
MX2020005879A (es) 2020-10-07
EP3720421A4 (en) 2021-09-15
US20200121640A1 (en) 2020-04-23
CN111565709A (zh) 2020-08-21
PH12020550788A1 (en) 2021-04-19
WO2019113543A1 (en) 2019-06-13
MA51056A (fr) 2020-10-14
US20210322373A1 (en) 2021-10-21
AU2018379078A1 (en) 2020-07-23
IL275182A (en) 2020-07-30
JP2021505673A (ja) 2021-02-18
KR20200097757A (ko) 2020-08-19
JP2023134671A (ja) 2023-09-27
JOP20200134A1 (ar) 2022-10-30
CL2020001495A1 (es) 2021-02-19
SG11202005158PA (en) 2020-06-29
US11344529B2 (en) 2022-05-31

Similar Documents

Publication Publication Date Title
CR20200291A (es) Composiciones y métodos para el tratamiento de enfermedades metabólicas
PH12020550341A1 (en) Niraparib formulations
SA518391624B1 (ar) Ror- منظمات جاما
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MX386256B (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
EA201690962A1 (ru) Составы
PH12017500841B1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
WO2018111315A8 (en) PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
NZ709803A (en) Compositions comprising 15-ohepa and methods of using the same
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
EA201790904A1 (ru) Новые производные пиразола в качестве ингибиторов nik
EA201790223A1 (ru) Водный препарат, содержащий парацетамол и ибупрофен
MY205909A (en) Low-dose brimonidine combinations and uses thereof
EA201790315A1 (ru) Модуляторы x-рецепторов печени
PH12016501519A1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EA202191683A1 (ru) Средство, содержащее 4-фенилбутират, для профилактики или лечения пресбиопии
MX357888B (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
MX2020000873A (es) Derivados de ácidos biliares marcados isotópicamente.
EA201792085A1 (ru) Смешанные дисульфидные конъюгаты тиенопиридиновых соединений и их применение
EA201792170A1 (ru) Производные индола
EA201690240A1 (ru) Новые соединения индазола и способ их получения